Hemodialysis
Drug research and approvals for hemodialysis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 180 studies of hemodialysis are recruiting on ClinicalTrials.gov, Health Canada has authorized 5 drug trials for it since 2013, and FDA has 2 approved and 7 open orphan designations naming it.
- Recruiting worldwide: 180
- Trials authorized in Canada: 5
- FDA orphan approvals: 2
- EU medicines: 0
- Six-Channel Wearable ECG for Prediction of Hyperkalemia in Hemodialysis PatientsNCT07947485 · Not reported · Chungnam National University Hospital · starts Nov 12, 2026
- A Study to Test the Safety of the Study Drug Fosmanogepix and How the Body Handles It in Adults With Severe Kidney…NCT07916181 · Phase 1 · Basilea Pharmaceutica · starts Oct 27, 2026
- Study of 3D Ultrasound for Support of Hemodialysis CannulationNCT07891741 · Not applicable · Sonavex, Inc. · starts May 7, 2026
- Physical Exercise in Patients With Chronic Kidney Disease in Hemodialysis (Pehedal-ESKD)NCT07820514 · Not applicable · Ricerca Nefrocenter · starts Jun 1, 2024
- Bioimpedance Spectroscopy (BIS): Fluid Changes in Hemodialysis PatientsNCT07803029 · Not applicable · Per Ivarsen · starts May 11, 2025
- Clinical Effectiveness and Resource Use in End-Stage Renal Disease Patients: Remote Patient Monitoring Across Dialysis…NCT07781124 · Not reported · Vantive Health LLC · starts Jun 17, 2026
- Bicarbonate HD StudyNCT07779200 · Not reported · East and North Hertfordshire NHS Trust · starts May 12, 2026
- Colchicine And Dialysis Patients; a Feasibility StudyNCT07762807 · Not applicable · King's College London · starts Apr 10, 2025
- Study of 3 Monoclonal Antibodies (REGN9933, REGN7508, and REGN9533) in Adult Participants With End-Stage Kidney Disease…NCT07759167 · Phase 1 · Regeneron Pharmaceuticals · starts Sep 17, 2026
| Aug 15, 2025 | Glucagon-like-peptide-1 receptor agonists in patients receiving maintenance dialysisOzempic | Unity Health Toronto | Ongoing |
| Jan 9, 2019 | Dialysis symptom control-restless legs syndrome trial (disco-rls trial)Ropinirole/ Gabapentin | Hamilton Health Sciences Corporation | Closed |
| Dec 17, 2018 | Effectiveness of ropinirole and gabapentin for the treatment of restless legs syndrome in patients on maintenance hemodialysis: a randomized, blinded,…Gabapentin / Ropinirole | Governors of The University of Alberta | Closed |
| Feb 19, 2016 | Pharmacokinetics and pharmacodynamics of apixaban in end-stage renal disease patients on hemodialysisApixaban | Jewish General Hospital | Closed |
| Sep 3, 2014 | Dose-ranging, parallel-group, randomized controlled trial of long-term ferumoxytol dosage strategies in hemodialysis patientsFerumoxytol | Dr François Madore | Pending |
| Oct 23, 2025 | Dehydrated alcoholTreatment of methanol poisoning in combination with hemodialysis in adults | BE Pharmaceuticals, LLC | Approved |
| Dec 8, 2000 | AntizoleUse for suspected or confirmed methanol poisoning, either alone or in combination with hemodialysis | Par Pharmaceuticals, Inc | Approved |
| Jun 15, 2017 | Human monoclonal antibody against phosphorylcholinePrevention of arteriovenous fistula or arteriovenous graft failure in patients with end stage renal disease receiving hemodialysis or… | Athera Biotechnologies, AB | Designated |
| May 10, 2012 | Sirolimus in an implantable collagen matrixPrevention of arteriovenous(AV) fistula or AV graft failure in patients with end stage renal disease, receiving hemodialysis or preparing… | SiraNex Bio, LLC | Designated |
| May 15, 2009 | TenecteplaseRestore function to hemodialysis catheters | Genentech, Inc. | Designated |
| Apr 3, 2009 | VonapanitasePrevention of arteriovenous fistula and arteriovenous graft failure in patients with chronic kidney disease (CKD) who are receiving… | Proteon Therapeutics, Inc. | Designated |
| Nov 4, 2003 | Tin ethyl etiopurpurinPrevention of access graft disease in hemodialysis patients | Miravant Medical Technologies | Designated |
| Oct 29, 1984 | EpoprostenolReplacement of heparin in patients requiring hemodialysis and who are at increased risk of hemorrhage. | Upjohn Company | Designated |
| Mar 29, 1984 | EpoprostenolReplacement of heparin in patients requiring hemodialysis and who are at risk of hemmorrage | Glaxo Wellcome Inc. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA